Researchers Find Knee Replacement Surgery May Have Minimal Effect on Quality of Life and Unattractive Economic Outcomes

Posted On March 29, 2017 By OrthoSpineNews In Recon, Top Stories /

(NEW YORK — April 1, 2017) Knee replacement surgery for patients with osteoarthritis, as currently used, provides minimal improvements in quality of life and is economically unattractive, according to a study led by Mount Sinai researchers and published today in the BMJ. However, if the procedure was only offered to patients with more severe symptoms, its effectiveness would rise, and its use would become economically more attractive as well, the researchers said.

“Given its limited effectiveness in individuals with less severely affected physical function, performance of total knee replacement in these patients seems to be economically unjustifiable,” said Bart Ferket, MD, PhD, Assistant Professor, Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai and lead author on the study. “Considerable cost savings could be made by limiting eligibility to patients with more symptomatic knee osteoarthritis. Our findings emphasize the need for more research comparing total knee replacement with less expensive, more conservative interventions, particularly in patients with less severe symptoms.”

About 12 percent of adults in the United States are affected by osteoarthritis of the knee. The annual rate of total knee replacement has doubled since 2000, mainly due to expanding eligibility to patients with less severe physical symptoms. The number of procedures performed each year now exceeds 640,000 at a total annual cost of about $10.2 billion, yet health benefits are higher in those with more severe symptoms before surgery.

A team of researchers from the Icahn School of Medicine at Mount Sinai and Erasmus University Medical Center in Rotterdam, the Netherlands, set out to evaluate the impact of total knee replacement on quality of life in people with knee osteoarthritis. They also wanted to estimate differences in lifetime costs and quality adjusted life years or QALYs (a measure of years lived and health during these years) according to level of symptoms.

They analyzed data from two U.S. cohort studies: one with 4,498 participants aged 45-79 with or at high risk for knee osteoarthritis from the Osteoarthritis Initiative (OAI), and the other involving 2,907 patients from the Multicenter Osteoarthritis Study (MOST). OAI participants were followed up for nine years and MOST patients were followed up for two years. Quality of life was measured using a recognized score of physical and mental function, known as SF-12, and using some osteoarthritis-specific quality of life scores.

They found that quality of life outcomes generally improved after knee replacement surgery, although the effect was small. The improvements in quality of life outcomes were found higher when patients with lower physical scores before surgery were operated on.

In a cost-effectiveness analysis, current practice was more expensive and in some cases seemed even less effective compared with scenarios in which total knee replacement was performed only in patients with lower physical function.

“Our findings show opportunity for optimizing delivery of total knee replacement in a cost-effective way, finding the patients who will benefit the most, delivering the treatment at the correct point in their disease progression, and optimizing the cost so we can deliver the benefit to all who need it,” said Madhu Mazumdar, PhD, Director of the Institute for Healthcare Delivery Science at the Mount Sinai Health System, Professor of Biostatistics, Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai, and co-author of the study.

Funding for the cohort studies used in the analysis was provided by the National Institutes of Health, Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer. Dr. Ferket is supported by the American Heart Association. The researchers have no competing interests to disclose.

About the Mount Sinai Health System

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is in the “Honor Roll” of best hospitals in America, ranked No. 15 nationally in the 2016-2017 “Best Hospitals” issue of U.S. News & World Report. The Mount Sinai Hospital is also ranked as one of the nation’s top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s, and Mount Sinai West are ranked regionally. Mount Sinai’s Kravis Children’s Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in “Best Children’s Hospitals.”

For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.

Two Cincinnati hospitals among first in nation to perform new kind of robotic surgery

Posted On March 27, 2017 By OrthoSpineNews In Recon, Robotics, Top Stories /

Mar 23, 2017 – By Barrett J. Brunsman, Staff reporter Cincinnati Business Courier

Surgeons at Mercy Health-Cincinnati’s Anderson Hospital and St. Elizabeth Healthcare in Edgewood are among the first in the nation to offer a total knee replacement using the Mako Robotic Arm-Assisted Surgery System.

Dr. Suresh Nayak performed Ohio’s first total knee replacement procedure using the robotic-arm-assisted technology together with the Stryker Triathlon Total Knee System at Anderson Hospital on March 7, according to Mercy Health.

Dr. Matthew Hummel of Commonwealth Orthopaedic Centers performed a similar total knee replacement surgery using the new robotic-arm-assisted technology at St. Elizabeth in Northern Kentucky on March 22.

The technology is available at only a handful of medical centers in the nation, a St. Elizabeth spokesman said. The U.S. Food & Drug Administration approved the robotic-arm-assisted technology for total knee replacement in August 2015, but the equipment won’t be available to most health systems until 2018.

The procedure is less invasive than traditional surgery, meaning patients often experience less pain after surgery, less hospitalization and more rapid recovery, according to St. Elizabeth. Patients also often feel better motion and a more natural-feeling knee after the surgery.

READ THE REST HERE

Stamford Health Names New Chair Of Orthopedic Surgery Department

Posted On March 23, 2017 By OrthoSpineNews In Recon /

By John Haffey – March 21, 2017

STAMFORD, Conn. — Dr. Charles “Chip” Cornell has been named chair of the newly created Department of Orthopedic Surgery at Stamford Health, effective March 1. As department chair, Cornell will be responsible for the direction of all orthopedic services, including subspecialty divisions and HSS Orthopedics at Stamford Health.

The hospital’s new collaboration with Hospital for Special Surgery was announced last month.

“We are proud to have someone of Dr. Cornell’s recognized leadership and surgical expertise join Stamford Health as we expand orthopedic services,” said Dr. Sharon Kiely, senior vice president of Medical Affairs and chief medical officer at Stamford Health. “This follows the announcement of our collaboration with Hospital for Special Surgery and complements our vision of further developing leading specialty services in orthopedics.”

Throughout his career, Cornell has studied the outcome of total knee replacement as treatment for osteoarthritis of the knee. His current research interests include investigating novel approaches to pain management following total knee replacement surgery as well as analysis of the benefit of implementing Clinical Pathways for total knee replacement. He is also collaborating on a study investigating the effect of pre-operative synovitis in patients with osteoarthritis of the knee and its effect on range of motion and stiffness following this procedure.

Cornell is professor of Clinical Orthopedic Surgery at Weill Cornell Medical College and an attending orthopedic surgeon at Hospital for Special Surgery. He served as clinical director of orthopedics for HSS beginning in 2006, and holds the Dr. Richard Laskin, chair in Orthopedic Surgery since 2011. Cornell has been active in the Resident and Medical School program throughout his career and recognized for his dedication to education, receiving the Philip Wilson Teaching Award three times.

To learn more about the new HSS Orthopedics at Stamford Health, click here.

HSS: Shortened KOOS is Valid

Posted On March 22, 2017 By OrthoSpineNews In Recon /

Elizabeth Hofheinz, M.P.H., M.Ed. • Wed, March 22nd, 2017

It’s a no-brainer…anyone would prefer to answer 7 survey questions as opposed to 42. Hurray for the researchers from Hospital for Special Surgery (HSS) in New York, who have confirmed that a seven-question patient survey on pain, function and quality of life is a valid and efficient tool for assessing patient outcomes following revision total knee replacement (TKR).

According to the March 14, 2017 news release, “The previous commonly used knee replacement survey was 42 questions often leaving physicians with partial, unusable information. The shorter survey, known as KOOS JR. (Knee Injury and Osteoarthritis Outcome Score), and its hip replacement counterpart, HOOS JR., have already been adopted for Medicare’s primary total joint replacement bundled payment program. HSS’ research presented at AAOS now provides peer-reviewed data that confirms KOOS JR. is a valid outcomes measure for knee replacement surgery.”

“At HSS, we are continually improving how we measure outcomes and KOOS JR. is a direct result of these efforts,” said Alexander McLawhorn, M.D., M.B.A., an orthopedic surgeon at HSS. “We saw a need for a shorter, more patient friendly survey in an area where outcomes data are essential to improving quality of care. In fact, knee replacement revisions, which are more complex than primary knee surgery, are under-studied in this regard.”

READ THE REST HERE

The robotic have-not: How J&J plans to woo hospitals, knee surgeons

Posted On March 22, 2017 By OrthoSpineNews In Recon, Robotics /

By ARUNDHATI PARMAR – MedCity News, March 17, 2017

Johnson & Johnson and Verily Life Sciences (formerly Google Life Sciences) have a joint venture to create the next generation of robotic surgery souped up with digital technologies in the future. (Watch out Intuitive Surgical.)

But when it comes to hip and knee replacement today, J&J Depuy Synthes is a robotic have-not.

Competitors have robots or are close to having something robotic in joint replacement.

On Tuesday, Stryker launched its total knee application on the expensive Mako robotduring the annual meeting of the American Academy of Orthopaedic Surgeons in San Diego. That same day at AAOS, Smith & Nephew previewed its hand-held robot-assisted device for total knee replacements in advance of a market release in the second quarter. And Zimmer-Biomet was also proudly displaying its robot on the exhibit floor — the Rosa robot acquired with the purchase of French firm Medtech SA – although the robot won’t be doing total knee replacements until 2018.

There is a general notion that robotics will gain ground in orthopedic surgery though the predictions around adoption pace vary greatly.

One analyst — Brandon Henry from RBC Capital Markets — believes Stryker will be the clear winner with the launch of its total knee on its Mako robotic system and will take market share away from Johnson & Johnson DePuy Synthes and Zimmer-Biomet in the next few years. Another — Richard Newitter from Leerink Partners — believes robotics adoption will be much more gradual and only in complex cases but still having one in the short term is better than not having one.

So in the meantime without a robot, how can J&J DePuy Synthes woo hospitals and knee surgeons, some of whom are part of Medicare’s mandatory 90-day bundled payment program called the Comprehensive Care for Joint Replacement.

Company executives are relying on the wide breadth of J&J’s knee offerings, its services chops and a new company-sponsored whitepaper that touts the economic value of its Attune Knee.

READ THE REST HERE

five-section-lumbar-spine-model-human-skeleton-model-with-font-b-pelvis-b-font-spine-Lumbar.jpg

Degree of spinal deformity affects hip replacement surgery success

Posted On March 20, 2017 By OrthoSpineNews In Recon, Spine /

PUBLIC RELEASE: 17-MAR-2017 – NYU LANGONE MEDICAL CENTER / NEW YORK UNIVERSITY SCHOOL OF MEDICINE

People with spinal deformity also requiring a total hip replacement are at greater risk for dislocation or follow-up revision surgery, suggesting that these higher-risk patients may benefit from a more personalized approach to their surgeries to reduce the risk of poorer outcomes.

A new study led by orthopaedic surgeons at NYU Langone Medical Center provides a greater understanding of exactly how spinal deformity interacts with the pelvis, potentially increasing risk despite implanting the artificial hip in what is traditionally considered a “safe zone” by surgeons.

“Surgeons should anticipate potential instability after performing a hip replacement in patients who have existing spinal deformity, and they should adjust their surgical plans accordingly,” says lead study author Aaron J. Buckland, MD, assistant professor of Orthopaedic Surgery in the division of Spine Surgery and director of spine research at NYU Langone.

The study was presented March 17, 2017 at the American Academy of Orthopaedic Surgeons (AAOS) 2017 Annual Meeting in San Diego, California. These findings also were published online December 27, 2016 in the Journal of Arthroplasty.

More than 310,000 hip replacements are performed in the U.S. each year, with rates dramatically increasing over the past two decades in younger adults 45 to 64 years of age who are active and living longer than ever before. An estimated 2.5 million Americans are currently living with hip replacements.

In a hip replacement, an artificial joint comprised of a ball and socket is implanted to replace the natural socket in the pelvis, enabling movement that is typical of the hip joint. For the past 40 years, surgeons have placed the socket (known as the acetabular cup) adjacent to the pelvic bone in a so-called “safe zone” — a position that is thought to reduce risk of dislocation. However, the new research suggests that placing the cup in the safe zone may not be enough to prevent dislocation in patients with spinal deformity.

Until now, no studies of the hip-spine relationship have focused on patients with sagittal spinal deformity, says Dr. Buckland. “Our research helps bridge any disconnect between surgeons who regularly treat spinal deformities and those who perform hip joint replacements, fostering more collaboration to improve patient outcomes,” he adds.

READ THE REST HERE

Medacta International Expands Relationship With OREF to Advance Orthopedic Research and Innovation

Posted On March 16, 2017 By OrthoSpineNews In Financial, Recon, Spine /

March 16, 2017

CHICAGO–(BUSINESS WIRE)–Medacta International, the privately held, family-owned global leader in the design of innovative joint replacement and spine surgery products, today reaffirmed its partnership with the Orthopaedic Research and Education Foundation (OREF) to advance new frontiers of orthopedic discovery. Effective immediately, and building upon their work together over the past two years, Medacta has increased its support and will now match resident gifts two-to-one, up from its original commitment of one-to-one. Importantly, this program encourages residents to engage in charitable giving at an early state in their careers and prioritizes OREF as a beneficiary of their philanthropy.

Since the program started in 2015, the Medacta Challenge raised more than $150,000 for OREF. This includes contributions to OREF’s Research Fund from Francesco Siccardi, Executive Vice President of Medacta International, and Eric Dremel, President of Medacta USA, who each pledged $20,000 to kick off the partnership and demonstrate their commitment to the initiative. Mr. Siccardi and Mr. Dremel were recognized for their gifts as members of OREF’s Visionary Research Society.

“We believe the next big innovation is always just around the corner and are excited that our expanded partnership with OREF will make already generous resident contributions even more impactful,” said Siccardi. “This partnership drives Medacta and OREF’s shared goal of providing the best possible care to improve the lives of patients around the globe.”

All gifts made to OREF through the Medacta Challenge help OREF achieve its mission of funding new and seasoned investigators in the orthopedic field. This funding may be used to support research in orthopedic trauma, total joint arthroplasty, soft tissue repair and regeneration, among other important topics. With Medacta’s increased commitment, the impact of resident donations will be tripled to provide investigators with necessary resources to conduct these important studies.

“OREF relies on the generosity of organizations like Medacta to continue supporting research in orthopaedics,” said David Lewallen, MD, OREF Board President. “The grants we provide enable innovators to push the envelope and be bold, effectively creating change in the orthopaedic discipline – ultimately providing patients with safer, better options, and a higher quality of life. None of this would be possible without our committed partners such as Medacta.”

Richard Santore, MD, Trustee and Chair of OREF’s Individual Development Committee, added, “We are particularly excited that Medacta’s matching gift program will not only support our investigators, but will encourage other individuals and companies to consider establishing additional creative concepts for making gifts to OREF. Working together to promote new studies and drive creative solutions will benefit us all and, most importantly, the patients we serve together. Medacta is to be commended for their leadership and generosity for this multi-year commitment to OREF.”

Since Medacta’s founding in 1999, the company has maintained a long tradition of prioritizing research and training, the foundations of orthopedics. Through training initiatives, such as the company’s M.O.R.E. Institute, Medacta promotes surgeon education and provides the tools for physicians to refine their skills. The company has trained over 5,000 surgeons at its learning centers, while its biennial M.O.R.E. International Symposium consistently attracts hundreds of renowned surgeons from across the world.

For more information about Medacta, please visit medacta.com or follow @Medacta on Twitter.

About Medacta

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter.

About the Orthopaedic Research and Education Foundation

Founded in 1955, the Orthopaedic Research and Education Foundation is a charitable 501(c)(3) organization committed to improving lives by supporting excellence in orthopaedic research. OREF is dedicated to supporting new investigators and is the premiere orthopaedic organization funding research across all specialties. A list of research and funding priorities is available at oref.org/grants. To learn more about OREF, please visit www.oref.org or follow @OREFtoday on Twitter.

Contacts

For Medacta International, Inc.
Jill Bongiorni, 516-729-2250
Jill@torchcomllc.com
or
For OREF
Karen Pubentz, 847-430-5113
pubentz@oref.org

DePuy Synthes Companies Announces New ATTUNE® Revision Fixed Bearing Tibial Base and Cemented Stem

Posted On March 16, 2017 By OrthoSpineNews In Recon /

SAN DIEGO, March 15, 2017 /PRNewswire/ — Today, DePuy Synthes*, part of the Johnson & Johnson Family of Companies, announced the launch of the first ATTUNE^® Knee revision options, the ATTUNE Revision Fixed Bearing Tibial Base and the 14×50 mm Cemented Stem. The Tibial Base is designed to address a range of patient needs, from complex primary to partial revision of ATTUNE Primary Knees. The announcement was made in San Diego, coinciding with the American Academy of Orthopaedic Surgeons Annual Meeting.

The ATTUNE Revision Fixed Bearing Tibial Base, which is compatible with either fixed bearing posterior stabilized or cruciate retaining tibial inserts, incorporates the proprietary technologies of the ATTUNE Knee such as the LOGICLOCK™ Tibial Base locking mechanism that is designed to enable enhanced kinematics, stability and wear reduction.¹ The ATTUNE Revision Fixed Bearing Tibial Base can be used with a 14×50 mm Cemented Stem that can be added intra-operatively at the discretion of the surgeon for patients with clinical needs that require supplemental fixation.

According to Rajit Kamal, Global Knee Platform Leader, DePuy Synthes Joint Reconstruction, “DePuy Synthes worked with renowned experts around the world to develop the ATTUNE Knee System. The ATTUNE Revision Fixed Bearing Tibial Base and Cemented Stem were developed to address more complex clinical needs and expand treatment options for patients. It will also extend DePuy Synthes leadership in the category of revision solutions.”

DePuy Synthes Companies developed the ATTUNE Knee System to improve the stability and motion of knee replacement, which are important to patient satisfaction. The ATTUNE Knee System can help patients return to their normal activities sooner than anticipated^2-3, while also enabling surgeons and health systems to improve clinical outcomes, reduce costs and increase patient satisfaction.

Implant survivorship data from the 2016 Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) confirmed positive early results for the primary ATTUNE Knee.⁴ These data add to other recent registry evidence which has shown that survivorship for the primary ATTUNE Knee compares favorably to other knee systems in its class.⁵ In addition, one-year results from two worldwide studies have shown improved patient reported outcomes measures with the primary ATTUNE Knee compared to other leading knee systems.⁶

About DePuy Synthes Companies
DePuy Synthes Companies, part of the Johnson & Johnson Family of Companies, provides one of the most comprehensive portfolios of orthopaedic solutions in the world. DePuy Synthes Companies solutions, in specialties including joint reconstruction, trauma, neurological, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the effectiveness and value of the ATTUNE Knee System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; manufacturing difficulties and delays; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns for health care products and services; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements”, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither DePuy Synthes nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

*DePuy Synthes presents the products and service of DePuy Synthes, Inc. and its affiliates

The third-party trademarks used herein are trademarks of their respective owners
DSUS/JRC/0217/2035 March 2017

References:

1. Leisinger, S., Hazebrouck, S., Deffenbaugh, D., Heldreth, M. (2011) Advanced fixed bearing TKA locking mechanism minimizes backside micromotion. International Society for Technology in Arthroplasty (ISTA) Annual Meeting.

2. Clatworthy, M. (2015). An Early Outcome Study of the ATTUNE® Knee System vs. the SIGMA® CR150 Knee System. DePuy Synthes Companies White Paper. DSUS/JRC/0814/0418.
In an IRB approved early outcomes study, physiotherapists collected data on 40 patients implanted with ATTUNE® Knees and 40 patients with SIGMA® CR150 knees. The results demonstrated that patients implanted with the ATTUNE Knee had statistically significant improvements in some early outcomes, other outcomes demonstrated a trend favoring the ATTUNE Knee, and some outcomes were equivalent

3. Etter, K., Lerner, J., de Moor, C, Yoo, A., Kalsekar, I. (2016). PMD10-Comparative Effectiveness of ATTUNE® Versus Triathlon™ Total Knee Systems: Real-World Length of Stay and Discharge Status.” Value in Health 19(3): A298.
Premier Perspective™ Database analysis including 38 hospitals, representing 1,178 primary, unilateral TKAs with the ATTUNE Knee and 5,707 primary, unilateral TKAs with Triathlon™. The analysis found that the patients implanted with the ATTUNE Knee had statistically shorter length of stay and were more frequently discharged home vs. a skilled nursing facility compared to the TKAs with Triathlon™.

4. Australian Orthopaedic Association National Joint Replacement Registry Annual Report. (2016). Tables KT9 and KT22. Retrieved from: https://aoanjrr.sahmri.com/documents/10180/275066/Hip%2C%20Knee%20%26%20Shoulder%20Arthroplasty

Smith & Nephew previews NAVIO™ Robotics-assisted Total Knee Application at AAOS ahead of full market release in Q2 2017

Posted On March 16, 2017 By OrthoSpineNews In Recon, Top Stories /

LONDON, March 14, 2017 /PRNewswire/ — Smith & Nephew (NYSE: SNN; LSE: SN), the global medical technology business, today announces the upcoming full market release of its NAVIO hand-held robotics-assisted total knee arthroplasty (TKA) system. Smith & Nephew will be hosting live hands-on demonstrations for surgeons at the 2017 Annual American Academy of Orthopaedic Surgeons meeting in San Diego, CA, March 15-17 (booth # 5133).

The NAVIO Surgical System total knee application is expected to enter full market release in the second quarter of 2017, 510(k) pending, with Smith & Nephew’s JOURNEY II, LEGION and GENESIS II Total Knee Systems.

The NAVIO robotic-assisted total knee application is designed to deliver consistent and accurate results through the utilization of a surgeon controlled robotics-assisted hand piece, coupled with NAVIO specific cut guides. This unique combination yields an intuitive and efficient workflow for the entire surgical team. In addition, the versatile NAVIO planning software enables precise implant alignment and ligament balance, without the need for a pre-operative CT scan. Eliminating the dependency on pre-operative imaging allows the surgeon to seamlessly plan for either a unicompartmental or total knee procedure at the time of surgery.

“I have experience with several robotic systems and my experience with the NAVIO Surgical System has been phenomenal. Both NAVIO UKA and TKA applications allow me freedom as a surgeon, unlike other robotic options, because it is imageless. I can easily plan and correct for significant deformities and retained hardware with confidence. I love the direct interface with the system itself, putting me back in control.

Additionally, the cost of the system including the capital investment, lack of advanced imaging and its portability make it affordable for both hospitals and ASCs” says Jimmy Chow, M.D, Director of Orthopaedics: Hip & Joint, Phoenix St. Luke’s Medical Center.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.

™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

SOURCE Smith & Nephew

BONESUPPORT™ Founder Lars Lidgren Receives the 2017 OREF Clinical Research Kappa Delta Award

Posted On March 16, 2017 By OrthoSpineNews In Biologics, Recon /

Lund, Sweden, 16 March, 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that its founder Lars Lidgren, is a member of a group of Swedish and US Knee and Hip surgeons from Lund and Gothenburg, Sweden, Boston and Rochester U.S. that has received the 2017 OREF Clinical Research Kappa Delta Award. The award was made for the group’s outstanding research contribution leading to improved prosthetic survival and patient outcomes.

The OREF Clinical Research Kappa Delta recognizes outstanding clinical research related directly to musculoskeletal disease or injury. Henrik Malchau, MD, PhD, part of the Swedish and US group, will present the study “Arthroplasty Implant Registries Over The Past Five Decades: Development, Current and Future Impact” The award will be given at the AAOS meeting, San Diego, California on Thursday, March 16 at 11:00 am in the Ballroom 20.

Lars Lidgren, M.D., Ph.D. Hon. Member AAOS., founder of BONESUPPORT, said: “I’m delighted that clinical research on joint replacements, one of the most common surgical procedures today, has gained this very prestigious award. I am confident that our long term research based on arthroplasty registries will continue to help shape the development of new innovative technologies to provide patients with improved orthopaedic outcomes.”

Contact Information

Citigate Dewe Rogerson

David Dible, Andrea Bici, Mark Swallow

+44 (0)20 7282 2949/1050/2948

bonesupport@citigatedr.co.uk

Notes to Editor

About the OREF Clinical Research Kappa Delta Award

This award recognizes outstanding clinical research related directly to musculoskeletal disease or injury. Eligible applicants must be members of the American Academy of Orthopaedic Surgeons, the Orthopaedic Research Society, the Canadian Orthopaedic Association, and the Canadian Orthopaedic Research Society. The winning paper is presented by the author at the Orthopaedic Research Society’s annual meeting, and the award is presented to the recipient by an OREF representative at the Academy’s annual meeting during the Kappa Delta Award presentations.

About BONESUPPORT™

BONESUPPORT has developed CERAMENT as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to 12 months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT BONE VOID FILLER (BVF) addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT BVF is commercially available in the U.S., EU, SE Asia and the Middle East.

CERAMENT’s distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT G and CERAMENT V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.

CERAMENT G and CERAMENT V have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT G and CERAMENT V are available in the EU.

BONESUPPORT was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT’s mission is to bring people with bone and joint diseases back to an active life. The Company is based in Lund, Sweden. www.bonesupport.com

BONESUPPORT™ is a registered trademark.

Recon

Elizabeth Hofheinz, M.P.H., M.Ed. • Wed, March 22nd, 2017

Contacts

Related Links